Targanta Therapeutics

Targanta Therapeutics Inc.Founded in 1997, Targanta Therapeutics Inc. operates out of Cambridge, US, and specializes in antibacterial treatments. The company underwent a significant change when it was acquired by The Medicines Co.00 each in October 2007.Targanta Therapeutics specializes in the development of innovative antibacterial treatments, primarily focusing on the antibiotic Oritavancin. Oritavancin is designed to combat resistant strains of Gram-positive bacteria, addressing critical healthcare challenges such as skin and soft tissue infections, as well as severe infections caused by resistant organisms. The effectiveness of Oritavancin has been demonstrated in various preclinical models, including studies on anthrax and osteomyelitis, thus highlighting its versatile application in treating serious infections.Targanta Therapeutics generates revenue through partnerships and collaborations with healthcare organizations and pharmaceutical companies focused on antibacterial solutions. Transaction structures typically involve agreements where Targanta supplies its flagship antibiotic, Oritavancin, to healthcare providers and distributors, who then offer the treatment to end-users such as hospitals and clinics. These transactions may include bulk purchasing agreements or licensing arrangements for the use of its proprietary technology in developed treatments.5 mn from October 2007 to further develop its antibiotic Oritavancin and explore new therapeutic applications. The company aims to expand into additional markets in Europe and Asia by 2009, targeting regions with rising resistance to bacterial infections.

1. Series C

   Feb 9, 2007

   Amount

   $70M

   Investors

   Locked